@HarshGMD profile picture
Harsh Golwala @HarshGMD

Interventional Cardiologist I Structural I # Program Director, SHD fellowship, Oregon Health & Science University, Portland

Joined April 2010
  • Tweets 1,811
  • Following 1,001
  • Followers 1,765
65 Photos and videos
Now Accepting Applications – Structural Heart Disease Fellowship at OHSU! >600 structural cases a year, lots of TAVRs, LAAO, Mitral/Tricuspids, PVLs, and ASD/PFO closure- only 1 structural fellow/year! Email: plesiaa@ohsu.edu
1
3
15
2,496
Interviewing for structural fellowship for academic year 2025-2026. Interested fellows are welcome to apply to OHSU. One of the leading centers in structural space with TAVR, TMVR, TTVR, LAAO and lot of cutting edge early feasibility trials- contact plesiaa@ohsu.edu with CV/LORs!
2
7
19
3,015
@OHSUCardFellows @OHSUCardio
1
502
Excellent #NYValves2024...thank you for the directors and planning committee @crfheart @jgranadacrf @PradeepYadavMD @ShariqShamimMD @kashishgoelmd @ZaidAlMarzooq ..Can't wait to be at #NYValves2025 with many new updates over the year..
7
696
Harsh Golwala retweeted
Omar Khalique@OKhaliqueMD
28 Mar 2024
thelancet.com/journals/lance…

Transcatheter aortic valve implantation in patients with high-risk symptomatic native aortic...

This study shows the safety and effectiveness of treating native aortic regurgitation using a dedicated transcatheter heart valve to treat patients with symptomatic moderate-to-severe or severe...

thelancet.com
1
4
11
2,298
Transcatheter aortic valve implantation in patients with high-risk symptomatic native aortic regurgitation (ALIGN-AR): a prospective, multicentre, single-arm study - The Lancet thelancet.com/journals/lance…

1
1
10
1,184
Harsh Golwala retweeted
MrBeast
@MrBeast
22 Jan 2024
I’m gonna give 10 random people that repost this and follow me $25,000 for fun (the $250,000 my X video made) I’ll pick the winners in 72 hours
376,181
2,529,450
1,862,234
284,612,178
Harsh Golwala retweeted
Chittur Sivaram MD MACP MACC
@CASivaram1
8 Jun 2023
💟 Congrats, Harsh Golwala and Firas Zahr on your collaborative editorial ⬇️🌟 doi.org/10.1016/j.jcin.2023.… @ACCinTouch @HarshGMD @SVRaoMD @Pooh_Velagapudi @noshreza @HeartOTXHeartMD @adityadoc1 @ZainAsadEP @iamritu @purviparwani @renujain19 @davidmcnam @dr_benoy_n_shah
1
8
22
6,209
Hospital Procedural Volume and Clinical Outcomes of Transcatheter Aortic Valve Replacement: United States Nationwide Readmission Database, 2016-2019 - Journal of the Society for Cardiovascular Angiography & Interventions jscai.org/article/S2772-9303…

Hospital Procedural Volume and Clinical Outcomes of Transcatheter Aortic Valve Replacement: United...

The number of hospitals offering transcatheter aortic valve replacement (TAVR) in the United States has increased exponentially over the past several years. Multiple prior studies have demonstrated...

jscai.org
1
1
10
Harsh Golwala retweeted
Edwards Lifesciences
@EdwardsLifesci
15 Sep 2022
Edwards Pascal Precision Transcatheter Valve Repair System Receives FDA Approval For Degenerative Mitral Regurgitation ir.edwards.com/news/news-det…

EDWARDS PASCAL PRECISION TRANSCATHETER VALVE REPAIR SYSTEM RECEIVES FDA APPROVAL FOR DEGENERATIVE...

Edwards Lifesciences Corporation (NYSE: EW), today announced the company's PASCAL Precision transcatheter valve repair system for transcatheter edge-to-edge repair (TEER) has received FDA approval...

ir.edwards.com
14
31
Harsh Golwala retweeted
Joaquin E. Cigarroa MD FACC MSCAI@JCigarroaMD
28 Aug 2022
Interventional cardiologist should be aware of and participate in RUC surveys. You can have a direct impact on your reimbursement. Our webinar series at the SCAI website scai.org/professional-develo… provides in-depth information on surveys and advice on member participation.
3
15
Harsh Golwala retweeted
Ahmed Teebi, MD MPH MSc(Ox)🗝️
@Teebi_MD
28 Aug 2022
🔥Our team rocking the stage this morning #ESC in Barcelona. Presenting analysis on #TAVR outcomes by procedural volume. We showed strong volume-mortality correlation in 260K #TAVR cases in🇺🇸 Thanks @HarshGMD for leading! #ESCCongress #esc2022 #ESC22 #MedTwitter #CardioTwitter
2
5
27
Questions about LAA closure (1/2): 1. TEE underestimates sizing- are there more patients ineligible for closure related to CT vs. TEE sizing as we screen more patients with CT? 2. Sizing of elliptical LAA vs. circular LAA on CT? E.g. 30 x 18 vs. 25 x 24 mm
3
2
10
2/2: 3. Despite good coverage on 45-day TEE, penetration of contrast seen on 45-day CT more often- how can we understand this better to tailor DAPT vs. OAC continuation or discontinuation. Thoughts? @MCoylewright @AGoldsweig @anvoramd @Drdevignair @DJ_Lakkireddy @drrakeshg1
1
1
6
@jgschwartzmd @SachinGoelMD @AlokSharma081 @sanghaimd @Pooh_Velagapudi @ShariqShamimMD @TheNarulaSeries @joewalshmd @docsaw @SidakpalP @drrahulpsharma @DrTomWaggoner @NeilGheewalaMD @dr_rothschild
2
Harsh Golwala retweeted
Joaquin E. Cigarroa MD FACC MSCAI@JCigarroaMD
30 May 2022
CCI Manuscript on SDM and Quality Published: Integrating shared decision-making in coronary revascularization with quality assurance programs Lloyd W. Klein MD, H. Vernon Anderson MD, Joaquin Cigarroa MD First published: 29 May 2022 doi.org/10.1002/ccd.30222

Integrating shared decision‐making in coronary revascularization with quality assurance programs

Click on the article title to read more.

onlinelibrary.wiley.com
6
7
25
Harsh Golwala retweeted
Pooja Prasad, MD@poojaprasad91
30 Apr 2022
Despite higher STS score the intermediate-term mortality risk and outcomes after TAVI were comparable in patients with and without prior CABG at our center. pubmed.ncbi.nlm.nih.gov/3538… Important work led by OHSU fellow Kris Kumar @OHSUCardFellow
4
9
What is your anti platelet/anticoagulation strategy 6 weeks post watchman if everything looks ok @ShariqShamimMD @adnanalkhouli @MCoylewright @CJChungMD @Gupta_MD @SanonSaurabh @sanghaimd @DJ_Lakkireddy @drrakeshg1 @anvoramd @TheNarulaSeries
30% ASA 81 mg daily x12 m
0% ASA 325 mg daily x 12m
68% ASA 81/Plavix 75 mgx 6 m
2% Low dose DOAC x 6 m
40 votes • Final results
2
1
1
Harsh Golwala retweeted
OHSU Cardiology Fellowship@OHSUCardFellows
22 Mar 2022
A wonderful review of the mechanisms, pharmacokinetics and key clinical trials of platelet inhibitors in STEMI by our very own 3rd year fellow Kris Kumar and interventional cardiologist @HarshGMD ! amjmed.com/article/S0002-934…
2
7
Load more